FDA Grants Elotuzumab Triplet Priority Review for Myeloma

August 23, 2018 – The FDA has granted a priority review to a supplemental biologics license application (sBLA) for elotuzumab for use in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor (PI). The sBLA was submitted based on the phase II ELOQUENT-3 trial, in which the addition of elotuzumab … (leggi tutto)